CD19 and plasma cell myeloma: In a phase I trial for multiple myeloma, patients treated with 24-h manufactured anti-CD19 CAR T-cells tolerated the infusion and showed a 98% overall response rate, with CAR T-cells detectable in 71% of patients at 12 months [181].